Canadian Agency for Drugs and Technologies in Health 2016-10-31
Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines
Related Questions
Radium-223 has an overall survival benefit and lower hematologic toxicity, but at a significantly increased cost. Does the cost-effectiveness fa...
New answer by Radiation Oncologist at Comprehensive Cancer Centers of Nevada (January 20, 2017)
I use radium 223 in all patients unless thier performance staus is poor ECOG-2 or they have significant visceral disease. In those cases it may difficult to get authorization ...